Zacks: Brokerages Anticipate Alpine Immune Sciences Inc (NASDAQ:ALPN) Will Post Earnings of -$0.55 Per Share

Wall Street analysts predict that Alpine Immune Sciences Inc (NASDAQ:ALPN) will announce ($0.55) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Alpine Immune Sciences’ earnings, with estimates ranging from ($0.67) to ($0.36). Alpine Immune Sciences posted earnings of ($0.80) per share during the same quarter last year, which would suggest a positive year over year growth rate of 31.3%. The company is expected to announce its next earnings report on Monday, March 16th.

According to Zacks, analysts expect that Alpine Immune Sciences will report full year earnings of ($2.54) per share for the current fiscal year, with EPS estimates ranging from ($2.63) to ($2.32). For the next financial year, analysts anticipate that the business will post earnings of ($2.34) per share, with EPS estimates ranging from ($2.97) to ($1.42). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Alpine Immune Sciences.

Alpine Immune Sciences (NASDAQ:ALPN) last released its quarterly earnings data on Wednesday, November 13th. The biotechnology company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.06. The company had revenue of $0.29 million during the quarter, compared to the consensus estimate of $0.38 million.

ALPN has been the subject of several recent analyst reports. Zacks Investment Research downgraded Alpine Immune Sciences from a “buy” rating to a “hold” rating in a report on Monday. Piper Jaffray Companies lowered their price target on Alpine Immune Sciences to $8.00 and set an “overweight” rating for the company in a report on Wednesday, November 13th. They noted that the move was a valuation call. Finally, ValuEngine upgraded Alpine Immune Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, January 15th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $9.56.

Several institutional investors have recently made changes to their positions in the business. Hikari Power Ltd increased its holdings in shares of Alpine Immune Sciences by 52.9% in the third quarter. Hikari Power Ltd now owns 185,587 shares of the biotechnology company’s stock worth $735,000 after acquiring an additional 64,224 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Alpine Immune Sciences by 67.7% in the second quarter. Vanguard Group Inc. now owns 202,582 shares of the biotechnology company’s stock worth $853,000 after acquiring an additional 81,800 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Alpine Immune Sciences in the second quarter worth about $90,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Alpine Immune Sciences by 10.8% in the second quarter. Renaissance Technologies LLC now owns 106,261 shares of the biotechnology company’s stock worth $447,000 after acquiring an additional 10,400 shares in the last quarter. Institutional investors own 46.80% of the company’s stock.

NASDAQ ALPN traded down $0.43 on Monday, reaching $3.37. The company had a trading volume of 22,696 shares, compared to its average volume of 13,720. Alpine Immune Sciences has a 52 week low of $2.25 and a 52 week high of $8.24. The stock’s 50 day moving average is $3.63 and its 200-day moving average is $3.74. The stock has a market cap of $62.65 million, a price-to-earnings ratio of -1.22 and a beta of 1.86. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.47.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.

Further Reading: How Do You Calculate Return on Equity (ROE)?

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.